Atrial fibrillation, anticoagulation management and risk of stroke in the Cardiomyopathy/Myocarditis registry of the EURObservational Research Programme of the European Society of Cardiology.

Autor: Mizia-Stec K; First Department of Cardiology, School of Medicine in Katowice, Medical University of Silesia, 47 Ziołowa St., Katowice, 40-635, Poland., Caforio ALP; Division of Cardiology, Department of Cardiological Thoracic and Vascular Sciences and Public Health, University of Padua, Padua, Italy., Charron P; Centre de Référence des Maladies Cardiaques Héréditaires, Assistance Publique-Hôpitaux de Paris, ICAN, Hôpital Pitié-Salpêtrière, Paris, France.; Sorbonne Université, INSERM UMR1166, Paris, France., Gimeno JR; Cardiac Department, Hospital Universitario Virgen de la Arrixaca, Murcia, Spain., Elliott P; Inherited Cardiac Diseases Unit, Barts Heart Centre, St Bartholomew's Hospital and University College London (UCL), London, UK., Kaski JP; Centre for Inherited Cardiovascular Diseases, Great Ormond Street Hospital, London, UK., Maggioni AP; EURObservational Research Programme, European Society of Cardiology, Sophia Antipolis, France.; ANMCO Research Center, Florence, Italy., Tavazzi L; Maria Cecilia Hospital, GVM Care and Research, Cotignola, Italy., Rigopoulos AG; Mid-German Heart Center, Department of Internal Medicine III, Division of Cardiology, Angiology and Intensive Medical Care, University Hospital Halle, Martin-Luther-University Halle-Wittenberg, Halle, Germany., Laroche C; EURObservational Research Programme, European Society of Cardiology, Sophia Antipolis, France., Frigy A; Clinical County Hospital, Târgu Mureș, Romania., Zachara E; San Camillo Hospital, Rome, Italy., Pena-Pena ML; Cardiac Imaging and Inherited Cardiac Diseases Unit, Department of Cardiology, Virgen del Rocio University Hospital, Seville, Spain., Olusegun-Joseph A; Cardiology Unit, Department of Medicine, College of Medicine, University of Lagos, Lagos University Teaching Hospital, Lagos, Nigeria., Pinto Y; Academic Medical Center, Amsterdam, The Netherlands., Sala S; San Raffaele Hospital, Milan, Italy., Drago F; Department of Pediatric Cardiology, Bambino Gesù Children's Hospital and Research Institute, Rome, Italy., Blagova O; I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia., Reznik E; Russian National Research Medical University named after N.I. Pirogov, Moscow, Russia., Tendera M; Department of Cardiology and Structural Heart Disease, School of Medicine in Katowice, Medical University of Silesia, Katowice, Poland.
Jazyk: angličtina
Zdroj: ESC heart failure [ESC Heart Fail] 2020 Dec; Vol. 7 (6), pp. 3601-3609. Date of Electronic Publication: 2020 Sep 17.
DOI: 10.1002/ehf2.12854
Abstrakt: Aims: Cardiomyopathies are a heterogeneous group of disorders that increase the risk for atrial fibrillation (AF). The aim of the study is to assess the prevalence of AF, anticoagulation management, and risk of stroke/transient ischaemic attack (TIA) in patients with cardiomyopathy.
Methods and Results: Three thousand two hundred eight consecutive adult patients with cardiomyopathy (34.9% female; median age: 55.0 years) were prospectively enrolled as part of the EURObservational Research Programme Cardiomyopathy/Myocarditis Registry. At baseline, 903 (28.2%) patients had AF (29.4% dilated, 27.5% hypertrophic, 51.5% restrictive, and 14.7% arrhythmogenic right ventricular cardiomyopathy, P < 0.001). AF was associated with more advanced New York Heart Association class (P < 0.001), increased prevalence of cardiovascular risk factors and co-morbidities, and a history of stroke/TIA (P < 0.001). Oral anticoagulation was administered in 71.7% of patients with AF (vitamin K antagonist: 51.6%; direct oral anticoagulant: 20.1%). At 1 year follow-up, the incidence of cardiovascular endpoints was as follows: stroke/TIA 1.85% (AF vs. non-AF: 3.17% vs. 1.19%, P < 0.001), death from any cause 3.43% (AF vs. non-AF: 5.39% vs. 2.50%, P < 0.001), and death from heart failure 1.67% (AF vs. non-AF: 2.44% vs. 1.31%, P = 0.033). The independent predictors for stroke/TIA were as follows: AF [odds ratio (OR) 2.812, P = 0.005], history of stroke (OR 7.311, P = 0.010), and anaemia (OR 3.119, P = 0.006).
Conclusions: The study reveals a high prevalence and diverse distribution of AF in patients with cardiomyopathies, inadequate anticoagulation regimen, and high risk of stroke/TIA in this population.
(© 2020 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of the European Society of Cardiology.)
Databáze: MEDLINE
Externí odkaz: